Month: June 2022
Excerpt from the Press Release: REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that five new regional private insurance plans have issued positive coverage policies of Aquablation therapy for the surgical treatment of benign…
Read More
Keros Therapeutics will be hosting a conference call and webcast today, June 10, 2022, at 8:00 a.m. Eastern time. Excerpt from the Press Release: LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for…
Read More
Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response to emavusertib Promising clinical and preclinical analysis showcases the potential of emavusertib in treating pCNSL Excerpt from the Press Release: LEXINGTON, Mass., June 10, 2022 /PRNewswire/ — Curis, Inc.…
Read More
— WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment (TME) immunosuppression relative to conventional natural killer (NK) cells — — WU-NK-101 demonstrated robust anti-tumor activity in vitro and in vivo in preclinical models of acute myeloid leukemia (AML) — — Data support the development of WU-NK-101 for AML and solid tumor indications —…
Read More
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, and cardiac safety in lymphoma patients treated with VIP152 Excerpt from the Press Release: PALO ALTO, Calif., June 10, 2022 (GLOBE…
Read More
– Long-term data at the European Hematology Association (EHA) 2022 Congress expands understanding of the impact of Genentech medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatment– – Updated data from Phase III CLL14 study of Venclexta (venetoclax) plus Gazyva (obinutuzumab) showed more than…
Read More
Excerpt from the Press Release: ATHENS, Ga. and LOS GATOS, Calif., June 9, 2022 /PRNewswire/ — CyanVac LLC, a clinical-stage biopharmaceutical company developing intranasal vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced preclinical data in a hamster model using CVXGA1, a COVID-19 vaccine candidate currently in Phase 1 clinical trials. The data show that CVXGA1,…
Read More
Excerpt from the Press Release: SAN DIEGO, June 2, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7…
Read More
Excerpt from the Press Release: SAN DIEGO & HOUSTON–(BUSINESS WIRE)–National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and…
Read More
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein…
Read More